b'POWERING CURES Our unwavering commitment to funding research that discovers and accelerates treatment advances for pediatric cancer continued in 2021 as we invested $2.3 million in research programs. PCRF supports scientists and path-breakers who representthe future of pediatric cancer treatment.RESEARCH IN ACTION:TWO SNAPSHOTSINNOVATIVE VENTUREINVENTIVE SOLUTIONSPHILANTHROPY EXPANDSTHAT HELP KIDS COPEOUR IMPACTWhile advancing research is our mission, we like to advance opportunities that innovate the ins and outs of day-to-day treatments for kids with cancer, too. That is why we were quick to respond when Hope for Henry Foundation approached us with a funding request. Their groundbreaking Ashley Plant-Fox, MD Elliot Stieglitz, MD Our efforts to accelerate research go beyond fundingpediatric patient incentive programs improve coping skills and Ann & Robert H. Lurie ChildrensUniversity of California, San Franciscotrailblazing researchers. We seized the opportunity tomedical outcomes for kids whose serious, chronic illnesses Hospital of Chicago Benioff Childrens Hospital have a bigger impact by investing in a biotech companyrequire lengthy hospitalizations. As the kids accomplish their called OncoHeroes Biosciences that is the first companymedical challenges, Hope for Henry rewards them with Hope Pediatric brain tumors represent the second most common cancerJuvenile myelomonocytic leukemia (JMML) is a blood cancerto focus 100 percent of its efforts on the developmentfor Henry Bucks, which they earn and exchange for gifts that type in children and are the number one cause of cancer-relatedthat affects young children and is difficult to diagnose andof new, innovative drugs specifically for children withmotivate them to do what they need to do to get better. In mortality in childhood. Diffuse intrinsic pontine glioma (DIPG) is atreat. Currently available therapies cure only half of patients,cancer. Our investment supports the Companysspring 2021, PCRF awarded Hope for Henry our first grant to devastating pediatric brain cancer, typically found in children ageswith many children experiencing an aggressive disease courseefforts to build a pipeline of pediatric oncology drugsdevelop rewards materials to help kids better understand the 5-8 years. It has a rapid onset of symptoms over a period of weekswhile some patients require minimal treatment at all. Dr Stieglitzby licensing discontinued assets for development inpath ahead. This incentive program helps kids navigate the and no known treatment at this time.The work of Dr. Plant-Foxdeveloped a test that can stratify patients with newly diagnosedpediatric cancer and obtaining the pediatric licensessteps necessary to complete challenging medical procedures represents a critical step towards giving kids diagnosed with thisof oncology therapies now being developed for adultlike proton beam therapy, MRIs, dressing changes, port access, deadly brain cancer hope for a healthy future. Dr Plant-Fox and herJMML to receive different amounts of therapy depending onindications. and more. Close to 1,000 kids have benefited from Super colleagues have created a vaccine with the goal of triggering thehow aggressive their leukemia is predicted to be. PCRF fundedRewards for Super Kids, with astounding results. immune system to recognize the genetic alterations known to bethis early-stage research, and now Dr Stieglitz and his team have present in DIPG tumors and, using immune cells known as T cells, toreceived NIH funding to activate a clinical trial to further support attack the tumor. They are also combining this vaccine therapy withdevelopment of this cutting-edge science.two other molecules to further expand the immune response. This combination immunotherapy for the treatment of newly diagnosed DIPG and diffuse midline glioma is moving forward in a first-of-its- Super job Hope for Henry! kind phase I/II clinical trial. The Will Irwin Memorial Fund at PCRF Thanks for getting kids makes our support of Dr Plant-Fox and her colleagues possible. over their trauma and letting them rediscovertheir smiles. As usual, PCRF was the first to fund this work.I think you would agree that the holy grail is to start withprivate funding that allows for follow-on federal funding,so mission accomplished in that sense!Elliot Stieglitz, MD11'